2. Kuhn A., Landmann A., Bonsmann G. The skin in autoimmune diseases – Unmet needs. Autoimmun Rev. 2016; 15(10): 948–54.https://dx.doi.org/10.1016/j.autrev.2016.07.013.

3. Micheletti R.G. Cutaneous vasculitis in rheumatologic disease: Current concepts of skin and systemic manifestations. Clin Dermatol. 2018; 36(4): 561–66. https://dx.doi.org/10.1016/j.clindermatol.2018.04.012.

4. Газданова А.А., Перков А.В., Лобанова К.К. с соавт. Дерматологические проявления ревматических заболеваний. Клиническая дерматология и венерология. 2022; 21(4): 548–554. [Gazdanova A.A., Perkov A.V., Lobanova K.K. et al. Dermatological manifestations of rheumatic diseases. Klinicheskaya dermatologiya i venerologiya = Clinical Dermatology and Venereology. 2022; 21(4): 548–554 (In Russ.)]. https://dx.doi.org/10.17116/klinderma202221041548. EDN: VRZFOY.

5. Chatzinasiou F., Polymeros D., Panagiotou M. et al. Generalized Pyoderma gangrenosum associated with ulcerative colitis: Successful treatment with infliximab and azathioprine. Acta Dermatovenerol Croat. 2016; 24(1): 83–85.

6. Кантемирова М.Г., Коровина О.А., Артамонова В.А. с соавт. Острая ревматическая лихорадка у детей: облик болезни в начале XXI века. Педиатрия. Журнал имени Г.Н. Сперанского. 2012 ;91(5): 17–21. [Kantemirova M.G., Korovina O.A., Artamonova V.A. et al. Acute rheumatic fever in children: The appearance of the disease at the beginning of the XXI century. Pediatriya. Zhurnal imeni G.N. Speranskogo = Pediatrics. Journal named after G.N. Speransky. 2012; 91(5): 17–21 (In Russ.)]. EDN: PHFUFH.

7. Белов Б.С., Кузьмина Н.Н., Медынцева Л.Г. Острая ревматическая лихорадка в XXI веке. Проблемы и поиск решений. Медицинский совет. 2016; (9): 96–101. [Belov B.S., Kuzmina N.N., Medyntseva L.G. Acute rheumatic fever in the XXI century: problems and search for solution. Meditsinskiy sovet = Medical Council. 2016; (9): 96–101 (In Russ.)].https://dx.doi.org/10.21518/2079-701X-2016-9-96-101. EDN: XTDENR.

8. Егорова О.Н, Белов Б.С., Карпова Ю.А. с соавт. Узловатая эритема: проблемы дифференциальной диагностики. Лечебное дело. 2012; 6: 64–70. [Egorova O.N., Belov B.S., Karpova Yu.A. et al. Erythema nodosum: Problems of differential diagnosis. Lechebnoe delo = General Medicine. 2012; 6: 64–70 (In Russ.)]. EDN: UHNCZR.

9. Miller T., Aung Y., Blundell D., Kona A.S.E.S.A. Unusual presentation of rheumatic fever in a 3-year-old child in the UK. BMJ Case Rep. 2020; 13(9): e232595. https://dx.doi.org/10.1136/bcr-2019-232595.

10. Aypar E., Demirtas D., Aykan H.H. et al. A girl with Henoch Schonlein purpura associated with acute rheumatic fever and review of literature. Turk J Pediatr. 2018; 60(5): 576–80. https://dx.doi.org/10.24953/turkjped.2018.05.017

11. Conforti A., Di Cola I., Pavlych V. et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev. 2021; 20(2): 102735. https://dx.doi.org/10.1016/j.autrev.2020.102735.

12. Cugno M., Gualtierotti R., Meroni P.L., Marzano A.V. Inflammatory joint disorders and neutrophilic dermatoses: A comprehensive review. Clin Rev Allergy Immunol. 2018; 54(2): 269–81. https://dx.doi.org/10.1007/s12016-017-8629-0.

13. Lora V., Cerroni L., Cota C. Skin manifestations of rheumatoid arthritis. G Ital Dermatol Venereol. 2018; 153(2): 243–55.https://dx.doi.org/10.23736/S0392-0488.18.05872-8.

14. Chua-Aguilera C.J., Moller B., Yawalkar N. Skin manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritides. Clin Rev Allergy Immunol. 2017; 53(3): 371–93. https://dx.doi.org/10.1007/s12016-017-8632-5.

15. Jakez-Ocampo J., Atisha-Fregoso Y., Llorente L. Pancytopenia as manifestation of nonarticular felty syndrome. J Clin Rheumatol. 2021; 27(8S): S613–S614. https://dx.doi.org/10.1097/RHU.0000000000000906.

16. Parisis D., Chivasso C., Perret J. et al. Current state of knowledge on primary Sjogren’s syndrome, an autoimmune exocrinopathy. J Clin Med. 2020; 9(7): 2299. https://dx.doi.org/10.3390/jcm9072299.

17. Generali E., Costanzo A., Mainetti C., Selmi C. Cutaneous and mucosal manifestations of Sjogren’s syndrome. Clin Rev Allergy Immunol. 2017; 53(3): 357–70. https://dx.doi.org/10.1007/s12016-017-8639-y.

18. Hile G.A., Lowe L., Kahlenberg J.M. Cutaneous purpura of Sjogren syndrome successfully treated with hydroxychloroquine. JAAD Case Rep. 2017; 3(4): 326–28. https://dx.doi.org/10.1016/j.jdcr.2017.04.011.

19. Roguedas A.M., Youinou P., Lemasson G. et al. Primary Gougerot–Sjogren syndrome: A dermatological approach. J Eur Acad Dermatol Venereol. 2006; 20(3): 243–47. https://dx.doi.org/10.1111/j.1468-3083.2006.01441.x.

20. Wey S.J., Chen Y.M., Lai P.J., Chen D.Y. Primary Sjogren syndrome manifested as localized cutaneous nodular amyloidosis. J Clin Rheumatol. 2011; 17(7): 368–70. https://dx.doi.org/10.1097/RHU.0b013e31823209ba.

21. Bitar C., Menge T.D., Chan M.P. Cutaneous manifestations of lupus erythematosus: A practical clinicopathologic review for pathologists. Histopathology. 2022; 80(1): 233–50. https://dx.doi.org/10.1111/his.14440.

22. Воробьева Л.Д., Асеева Е.А., Соловьев С.К. с соавт. Токсический эпидермальный некролиз как вариант тяжелого поражения кожи при системной красной волчанке. Научно-практическая ревматология. 2018; 56(6): 785–790. [Vorobyeva L.D., Aseeva E.A., Solovyev S.K. et al. Toxic epidermal necrolysis as a variant of severe skin lesions in systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018; 56(6): 785–790 (In Russ.)].https://dx.doi.org/10.14412/1995-4484-2018-785-790. EDN: IEWFCM.

23. Zhou W., Wu H., Zhao M., Lu Q. New insights into the progression from cutaneous lupus to systemic lupus erythematosus. Expert Rev Clin Immunol. 2020; 16(8): 829–37. https://dx.doi.org/10.1080/1744666X.2020.1805316.

24. Torres Saavedra F.A., Campo L.R., Mendez M.V. et al. Bullous lupus as the first manifestation of systemic lupus erythematosus in the pediatric population: A diagnostic challenge in daily practice. Lupus. 2020; 29(14): 1937–42. https://dx.doi.org/10.1177/0961203320950814.

25. Stanton M., Tiwari V. Polyarteritis Nodosa. 2021; In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021. PMID: 29489258.

26. De Virgilio A., Greco A., Magliulo G. et al. Polyarteritis nodosa: A contemporary overview. Autoimmun Rev. 2016; 15(6): 564–70.https://dx.doi.org/10.1016/j.autrev.2016.02.015.

27. Jansen T.M., Hoff N.P. Kutane Polyarteriitis nodosa: Eine seltene Ursache chronischer Ulzera. Hautarzt. 2015; 66(10): 720–22. [Jansen T.M., Hoff N.P. Cutaneous polyarteritis nodosa: A rare cause of chronic ulcers. Hautarzt = The Dermatologist. 2015; 66(10): 720–22 (In German)]. https://dx.doi.org/10.1007/s00105-015-3678-x.

28. Turska M., Parada-Turska J. Cutaneous polyarteritis nodosa. Wiad Lek. 2018; 71(1): 73–77. [Turska M., Parada-Turska J. Cutaneous polyarteritis nodosa. Wiad Lek = Medical News. 2018; 71(1): 73–77 (In Polish)].

29. Adigun R., Goyal A., Bansal P., Hariz A. Systemic Sclerosis. 2021; In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021. PMID: 28613625.

30. Нашатырева М.С., Трофименко И.Н., Черняк Б.А. Интерстициальное поражение легких при системной склеродермии (обзор литературы и собственное клиническое наблюдение). Пульмонология. 2020; 30(1): 102–108. [Nashatyreva M.S., Trofimenko I.N., Chernyak B.A. Interstitial lung lesion in systemic scleroderma (literature review and personal observation). Pulmonologiya = Pulmonology. 2020; 30(1): 102–108 (In Russ.)]. https://dx.doi.org/10.18093/0869-0189-2020-30-1-102-108. EDN: HIVWSP.

31. Prudhvi K., Jonnadula J., Kutti Sridharan G., Dominguez M. Systemic sclerosis with renal crisis and pericardial effusion. Clin Case Rep. 2020; 8(12): 3656–57. https://dx.doi.org/10.1002/ccr3.3467.

32. Ferreli C., Gasparini G., Parodi A. et al. Cutaneous manifestations of scleroderma and scleroderma-like disorders: A comprehensive review. Clin Rev Allergy Immunol. 2017; 53(3): 306–36. https://dx.doi.org/10.1007/s12016-017-8625-4.

33. Sandler R.D., Matucci-Cerinic M., Hughes M. Musculoskeletal hand involvement in systemic sclerosis. Semin Arthritis Rheum. 2020; 50(2): 329–334. https://dx.doi.org/10.1016/j.semarthrit.2019.11.003.

34. Орлова Е.В., Плиева Л.Р., Пятилова П.М., Новосартян М.Г. Дерматомиозит: клинический случай и обзор литературы. РМЖ. 2017; 25(11): 850–852. [Orlova E.V., Plieva L.R., Pyatilova P.M., Novosartian M.G. Dermatomyositis: A clinical case and literature review. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2017; 25(11): 850–852 (In Russ.)]. EDN: WYQWFX.

35. Дикарева Е.А., Величанская О.Г. Дерматомиозит (клинический случай). Вестник Витебского государственного медицинского университета. 2019; 18(2): 116–122 [Dikareva E.A., Velichanskaya O.G. Dermatomyositis (clinical case). Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta = Bulletin of Vitebsk State Medical University. 2019; 18(2): 116–122 (In Russ.)].https://dx.doi.org/10.22263/2312-4156.2019.2.116. EDN: ZYNUUT.

36. Гаджимурадов М.Н. К клинике дерматомиозита. Клиническая дерматология и венерология. 2017; 16(4): 31–34. [Gadzhimuradov M.N. Clinical presentation of dermatomyositis. Klinicheskaya dermatologiya i venerologiya = Clinical Dermatology and Venereology. 2017; 16(4): 31–34 (In Russ.)]. https://dx.doi.org/10.17116/klinderma201716431-34. EDN: ZGYYTV.

37. Meier K., Schloegl A., Poddubnyy D., Ghoreschi K. Skin manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020; 12: 1759720X20975915. https://dx.doi.org/10.1177/1759720X20975915.

38. Ye C., Li W. Cutaneous vasculitis in a patient with ankylosing spondylitis: A case report. Medicine (Baltimore). 2019; 98(3): e14121. https://dx.doi.org/10.1097/MD.0000000000014121.

39. Armstrong A.W., Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020; 323(19): 1945–60. https://dx.doi.org/10.1001/jama.2020.4006.

40. Hadeler E., Mosca M., Hong J. et al. Nail psoriasis: A review of effective therapies and recommendations for management. Dermatol Ther (Heidelb). 2021; 11(3): 799–831. https://dx.doi.org/10.1007/s13555-021-00523-x.

41. Thomas L., Azad J., Takwale A. Management of nail psoriasis. Clin Exp Dermatol. 2021; 46(1): 3–8.https://dx.doi.org/10.1111/ced.14314.

42. Mosca M., Hong J., Hadeler E. et al. Scalp psoriasis: A literature review of effective therapies and updated recommendations for practical management. Dermatol Ther (Heidelb). 2021; 11(3): 769–97. https://dx.doi.org/10.1007/s13555-021-00521-z.

43. Schneider J.M., Matthews J.H., Graham B.S. Reiter’s syndrome. Cutis. 2003; 71(3): 198–200.

44. Damevska K., França K., Nikolovska S., Gucev F. Adult-onset Still’s disease as a cutaneous marker of systemic disease. Clin Dermatol. 2019; 37(6): 668–74. https://dx.doi.org/10.1016/j.clindermatol.2019.07.034.

45. Narvaez Garcia F.J., Pascual M., Lopez de Recalde M. et al. Adult-onset Still’s disease with atypical cutaneous manifestations. Medicine (Baltimore). 2017; 96(11): e6318. https://dx.doi.org/10.1097/MD.0000000000006318.

46. Agha-Abbaslou M., Bensaci A.M., Dike O. et al.. Adult-onset Still’s disease: Still a serious health problem (A case report and literature review). Am J Case Rep. 2017; 18: 119–24. https://dx.doi.org/10.12659/ajcr.901846.

47. Lamprecht P., Gross W.L. Wegener’s granulomatosis. Herz. 2004; 29(1): 47–56. https://dx.doi.org/10.1007/s00059-004-2525-0.

48. Comfere N.I., Macaron N.C., Gibson L.E. Cutaneous manifestations of Wegener’s granulomatosis: A clinicopathologic study of 17 patients and correlation to antineutrophil cytoplasmic antibody status. J Cutan Pathol. 2007; 34(10): 739–47.https://dx.doi.org/10.1111/j.1600-0560.2006.00699.x.

49. Limtong P., Chanprapaph K., Vachiramon V., Ngamjanyaporn P. Cutaneous and extracutaneous manifestations of Behçet’s disease linked to its disease activity and prognosis. Clin Cosmet Investig Dermatol. 2020; 13: 639–47.https://dx.doi.org/10.2147/CCID.S265169.

50. Alpsoy E. Behçet’s disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016; 43(6): 620–32. https://dx.doi.org/10.111 1/1346-8138.13381.

51. Keyber G. Die gichtarthritis: pathogenese, diagnostik und behandlung. Dtsch Med Wochenschr. 2020; 145(14): 991–1005. [Keyber G. Gout arthritis: Pathogenesis, diagnostics and treatment. Dtsch Med Wochenschr = German Medical Weekly. 2020; 145(14): 991–1005 (In German)]. https://dx.doi.org/10.1055/a-1036-8348.

52. Clebak K.T., Morrison A., Croad J.R. Gout: Rapid evidence review. Am Fam Physician. 2020; 102(9): 533–38.

53. Gupta M.K., Singh J.A. Cardiovascular disease in gout and the protective effect of treatments including urate-lowering therapy. Drugs. 2019; 79(5): 531–41. https://dx.doi.org/10.1007/s40265-019-01081-5.

54. Mannes K., Thomas P.S. Sarcoidosis: Rarely a single system disorder. Breathe (Sheff). 2020; 16(4): 200207.https://dx.doi.org/10.1183/20734735.0207-2020.

55. Aggarwal H.K., Jain D., Mittal A., Dabas G. Isolated oculocutaneous sarcoidosis in a teenage male: A rare case report. Reumatismo. 2016; 68(2): 100–3. https://dx.doi.org/10.4081/reumatismo.2016.867.

56. Wanat K.A., Rosenbach M. Cutaneous sarcoidosis. Clin Chest Med. 2015; 36(4): 685–702. https://dx.doi.org/10.1016/j.ccm.2015.08.010.

57. Caplan A., Rosenbach M., Imadojemu S. Cutaneous sarcoidosis. Semin Respir Crit Care Med. 2020; 41(5): 689–99.https://dx.doi.org/10.1055/s-0040-1713130.

58. Descamps V., Bouscarat F. Manifestations cutanees de la sarcoidose. Ann Dermatol Venereol. 2016; 143(1): 39–50. [Descamps V., Bouscarat F. Cutaneous manifestations of sarcoidosis. Ann Dermatol Venereol. 2016; 143(1): 39–50 (In French)].https://dx.doi.org/10.1016/j.annder.2016.01.001.

59. Urzal J., Cimbron M., Mendonça T., Farinha F. Eosinophilic fasciitis (Shulman’s disease): Review and comparative evaluation of seven patients. Reumatologia. 2019; 57(2): 85–90. https://dx.doi.org/10.5114/reum.2019.84813.

60. Peckruhn M., Elsner P., Tittelbach J. Eosinophilic dermatoses. J Dtsch Dermatol Ges. 2019; 17(10): 1039–51.https://dx.doi.org/10.1111/ddg.13943.

61. Bilewicz-Stebel M., Bergler-Czop B., Stebel R. et al. Eosinophilic fasciitis – Clinical features and therapeutic management. Acta Dermatovenerol Croat. 2020; 28(3): 190–92.

62. Егорова О.Н., Белов Б.С. Панникулит: ревматологические аспекты. Современная ревматология. 2018; 12(2): 73–78. [Egorova O.N., Belov B.S. Panniculitis: Rheumatological aspects. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018; 12(2): 73–78 (In Russ.)]. https://dx.doi.org/10/14412/1996-7012-2018-2-73-78. EDN: UQXIPM.

63. Prieto-Pena D., Castaneda S., Atienza-Mateo B. et al. A review of the dermatological complications of giant cell arteritis. Clin Cosmet Investig Dermatol. 2021; 14: 303–12. https://dx.doi.org/10.2147/CCID.S284795

64. Румянцев П.О., Козлов И.Г., Колпакова Е.А. с соавт. IgG4-ассоциированные заболевания в эндокринологии. Проблемы эндокринологии. 2020; 66(2): 24–32. [Rumyantsev P.O., Kozlov I.G., Kolpakova E.A. et al. IgG4-related diseases in endocrinology. Problemy endokrinologii = Problems of Endocrinology. 2020; 66(2): 24–32 (In Russ.)]. https://dx.doi.org/10.14341/probl12285. EDN: XSAAEV.

65. Ishikawa Y., Terao C. Genetic analysis of IgG4-related disease. Mod Rheumatol. 2019; 30(1): 17–23.https://dx.doi.org/10.1080/14397595.2019.1621000.

66. Watanabe T., Minaga K., Kamata K. et al. Mechanistic insights into autoimmune pancreatitis and IgG4-related disease. Trends Immunol. 2018; 39(11): 874–89. https://dx.doi.org/10.1016/j.it.2018.09.005

67. Fujimoto M., Asai J., Asano Y. et al; Japanese Dermatological Association Guidelines. Wound, pressure ulcer and burn guidelines – 4: Guidelines for the management of connective tissue disease/vasculitis-associated skin ulcers. J Dermatol. 2020; 47(10): 1071–109. https://dx.doi.org/10.1111/1346-8138.15186.

68. Shanmugam V.K., Angra D., Rahimi H., McNish S. Vasculitic and autoimmune wounds. J Vasc Surg Venous Lymphat Disord. 2017; 5(2): 280–92. https://dx.doi.org/10.1016/j.jvsv.2016.09.006.